NASDAQ:IFRX
InflaRx N.V. Stock News
$1.58
+0 (+0%)
At Close: Jun 05, 2024
InflaRx Hosts R&D Event Highlighting the Promise of INF904
12:00pm, Wednesday, 05'th Jun 2024
JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a v
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data pr
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
07:30am, Wednesday, 08'th May 2024
JENA, Germany, May 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced f
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
07:30am, Wednesday, 24'th Apr 2024
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced tha
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
09:46am, Thursday, 21'st Mar 2024
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20.
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
07:00am, Thursday, 21'st Mar 2024
JENA, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
07:30am, Tuesday, 19'th Mar 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Appoints Jan Medina as Head of Investor Relations
07:30am, Thursday, 22'nd Feb 2024
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
07:30am, Thursday, 25'th Jan 2024
ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
07:00am, Thursday, 04'th Jan 2024
JENA, Germany, Jan. 04, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today toplin
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
11:18am, Friday, 01'st Dec 2023
InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
11:17am, Tuesday, 28'th Nov 2023
InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Monday, 06'th Nov 2023
InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
07:30am, Monday, 06'th Nov 2023
JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that t
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
07:30am, Wednesday, 01'st Nov 2023
JENA, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today fina
